

JP Morgan Healthcare Conference

A New Era of Pfizer R&D Productivity



Mikael Dolsten, M.D., Ph.D.
President, Worldwide R&D
January 8, 2018

Forward-Looking Statements


This presentation includes forward-looking statements about, among other things, our in-line products and product candidates, including anticipated regulatory submissions, data read-outs, approvals, performance, timing of exclusivity, potential benefits of Pfizer's products and product candidates, and anticipated future operating and financial performance that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. The forward-looking statements in this presentation speak only as of the original date of this presentation and we undertake no obligation to update or revise any of these statements.



Step Change in Pfizer R&D Productivity

Actual and potential blockbuster approvals (as of January 2018)

Up to 15 in 5 Years*



*Subject to attrition

Note: Examples reflect when cumulative Peak Year Sales are anticipated to exceed \$1B.



Potential 2018 Milestones

LATE STAGE

Xtandi®
nmCRPC PROSPER
Submission (US/EU)

talazoparib
EMBRACA
Submission (US/EU)

Xeljanz®
Ulcerative Colitis
Action Date (US/EU)

lorlatinib
NSCLC 2L
Action Date (US)

Bavencio®
NSCLC 2L
Phase 3 Data

Vyndaqel®
Cardiomyopathy
Phase 3 Data

rivipansel
Sickle Cell
Phase 3 Data

tanezumab
OA/CLBP Pain
Phase 3 Data

1H 2018

2H 2018

Ibrance® Combo
PDAC
Phase 1 Data

TFPI mAb
Hemophilia
Phase 1b/2 Data

Selective JAK's
Alopecia, Psoriasis
Phase 2 Data

Bavencio® Triplet
+ 4-1BB + OX-40
Phase 1 Data

JAK3
Rheumatoid Arthritis
Phase 1 Data

Anti IL-33
Atopic Derm
Phase 1 Data

PNG 20, GBS, VBIR1
Vaccines
Phase 1 & 2 Data

ACC, FK, GLP1
NASH
Phase 1 & 2 Data

EARLY STAGE

Discussion

